Capivasertib for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Jul 2020: Trial started, NCT04493853
  2. 30 Jul 2020: Trial registered, NCT04493853

The trials

NCT04493853: Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

State
Under way
Phase
Phase 3
People
1,012 taking part
Started
13 Jul 2020
Primary completion
7 Oct 2024
Arms
Capivasertib + Abiraterone
Results
Posted on the registry
  1. 13 Jul 2020: Trial started
  2. 30 Jul 2020: Trial registered
  3. 10 Sep 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Truqap.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.